The Altria Group, Inc. announced on its official website on April 25th that its first quarter performance of 2024 exceeded expectations, driven by price increases and rising demand for alternative tobacco products. The Q1 sales revenue amounted to $4.72 billion (€4.4 billion) after deducting excise taxes. The shipment volume of nicotine pouches On! increased by 32.1% compared to the previous quarter, reaching 25.2%. The shipment volume of NJOY consumables was approximately 10.9 million units, while NJOY devices totaled around 1 million units. Retail spending in multiple stores and convenience store channels in the US increased by 4.3% in the first quarter, a 0.6% increase from the previous quarter.
The report highlights include:
- The share of the American nicotine pouch category in the U.S. oral tobacco category has increased to 40.1%, a 13.8% rise compared to the previous year.
- The sale of a 10% stake (approximately 35 million shares) in the top beer maker, AB InBev, accounts for about one-fifth of its total holdings.
- The adjusted diluted earnings per share guidance range for the full year of 2024 is between $5.05 and $5.17, a 2% to 4.5% increase from $4.95 in 2023.
- Marlboro's retail share in the total cigarette category remains at 42.0%, unchanged from the previous year.
The CEO of Altria, Billy Gifford, stated during a press conference:
We have made significant progress in pursuing our vision, our high-margin traditional tobacco business continues to perform well in a challenging environment. Despite a lack of effective regulatory environment, we see continued early momentum in NJOY and believe our business is on track to meet full-year plans. We have also demonstrated our ongoing commitment to maximizing investment returns and providing strong shareholder returns through the sale of a partial stake in ABI and subsequently expanding our stock buyback program in March.
Notice
1. This article is provided exclusively for professional research purposes related to industry, technology and policy. Any reference to brands or products is made solely for the purpose of objective description and does not constitute an endorsement, recommendation, or promotion of any brand or product.
2. The use of nicotine products, including but not limited to cigarettes, e-cigarettes, and heated tobacco products, is associated with significant health risks. Users are required to comply with all relevant laws and regulations in their respective jurisdictions.
3. This article is strictly restricted from being accessed or viewed by individuals under the legal age.
Copyright
This article is either an original work by 2Firsts or a reproduction from third-party sources with the original source clearly indicated. The copyright and usage rights of this article belong to 2Firsts or the original source. Unauthorized reproduction, distribution, or any other unauthorized use of this article by any entity or individual is strictly prohibited. Violators will be held legally responsible. For copyright-related matters, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have utilized AI to enhance translation and editing efficiency. However, due to technical limitations, errors may occur. Readers are advised to refer to the sources provided for more accurate information.
This article should not be used as a basis for any investment decisions or advice, and 2Firsts assumes no direct or indirect liability for any errors in the content.
